

Transient receptor potential ankyrin 1 and calcium: Interactions and association with disease (Review)

FANGYAN HU, XIAOHUA SONG and DINGXIN LONG

Hunan Province Key Laboratory of Typical Environmental Pollution and Health Hazards, School of Public Health, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China

Received February 12, 2021; Accepted August 4, 2021

DOI: 10.3892/etm.2021.10897

Abstract. Calcium (Ca^{2+}) is an essential signaling molecule in all cells. It is involved in numerous fundamental functions, including cell life and death. Abnormal regulation of Ca^{2+} homeostasis may cause human diseases. Usually known as a member of the transient receptor potential (TRP) family, TRP ankyrin 1 (TRPA1) is the only member of the ankyrin subfamily identified in mammals so far and widely expressed in cells and tissues. As it is involved in numerous sensory disorders such as pain and pruritus, TRPA1 is a potential target for the treatment of neuropathy. The functions of TRP family members are closely related to Ca^{2+} . TRPA1 has a high permeability to Ca^{2+} , sodium and potassium ions as a non-selective cation channel and the Ca^{2+} influx mediated by TRPA1 is involved in a variety of biological processes. In the present review, research on the relationship between the TRPA1 channel and Ca^{2+} ions and their interaction in disease-associated processes was summarised. The therapeutic potential of the TRPA1 channel is highlighted, which is expected to become a novel direction for the prevention and treatment of health conditions such as cancer and neurodegenerative diseases.

Correspondence to: Professor Dingxin Long, Hunan Province Key Laboratory of Typical Environmental Pollution and Health Hazards, School of Public Health, Hengyang Medical School, University of South China, 28 West Changsheng Road, Hengyang, Hunan 421001, P.R. China
E-mail: dxlong99@163.com

Abbreviations: TRP, transient receptor potential; hTRPA1, human TRP ankyrin 1; CaM, calmodulin; AD, Alzheimer's disease; CYTO, cytoplasm; MITO, mitochondrion; ER, endoplasmic reticulum; SR, sarcoplasmic reticulum; PMCA, plasma membrane calcium ATPase; NCX, sodium calcium exchanger; CaBP, calcium-binding protein; VGCC, voltage-gated calcium channel; SOCC, store-operated calcium channel; IP3R, inositol trisphosphate receptor; SERCA, sarcoplasmic reticulum calcium ATPase; RyR, ryanodine receptor

Key words: transient receptor potential channels, TRPA1 cation channel, calcium, calcium channels, disease progression

Contents

1. Introduction
2. TRP family
3. Structure, distribution and physiological function of TRPA1
4. Ca^{2+} ions
5. Coupling TRPA1 with Ca^{2+} ions
6. Interaction between TRPA1 and Ca^{2+} in disease progression
7. Conclusions and perspectives

1. Introduction

Calcium ions (Ca^{2+}) are essential electrolytes in the body and have a fundamental role in regulating nerve cell excitation, neurotransmitter release, membrane integrity and muscle contraction. Thus, Ca^{2+} -triggered signalling pathways have an important role in neuron survival, plasticity and nerve transmission.

Over the past decade, transient receptor potential (TRP) channels have attracted increasing attention. TRP ankyrin 1 (TRPA1), a non-selective cation channel permeable to Ca^{2+} ions, is broadly distributed in various parts of the human body and is associated with various physiological and pathological states, such as sensations of cold and pain, as well as itchiness. Numerous studies have explored the role of the channel in the initiation and development of toxicity. The present review summarized the progress of research on the structure, function and distribution of TRPA1, and discussed diseases related to TRPA1 and Ca^{2+} .

2. TRP family

TRP family members are non-selective cation channels that were discovered in the visual system of the fruit fly *Drosophila melanogaster* (1). There are 28 known TRP cation channels with different structures and functions (2). All TRP channels have six transmembrane domains (S1-S6), and both N- and C-termini are located on the cytoplasmic side of the cell membrane. These proteins are thought to function as tetramers. TRP channels allow cations such as Ca^{2+} , Mg^{2+} , Na^+ and K^+ to pass through, which leads to cell depolarisation, influx of extracellular Ca^{2+} , release of Ca^{2+} from intracellular Ca^{2+} stores and binding of Ca^{2+} to calmodulin (CaM), ultimately affecting

cell proliferation and apoptosis. The functions of the TRP family are closely related to Ca^{2+} . For instance, TRP cation channel subfamily V member 5 (TRPV5) and TRPV6 are Ca^{2+} uptake channels in epithelial tissues with unique selectivity for Ca^{2+} [permeability (P) ratio $P_{\text{Ca}}/P_{\text{Na}} > 100$] (3).

In mammals, there are six TRP channel subtypes according to their amino acid sequence homology: The ankyrin TRP TRPA, the canonical TRPC and TRPV, the melastatin TRP termed TRPM, the polycystic TRP known as TRPP and the mucolipin TRP TRPML (4). Although all TRP channels share certain similarities in sequence and structure, there are significant differences in physiological functions, including cation selectivity, ligand binding and sensitivity to temperature and other environmental conditions among family members (5). The members of TRPV subfamily are considered to be heat sensors, nociceptive sensors, mechano-sensors and osmo-sensors (6,7) and the majority of TRPM subfamily members are implicated in taste, gastric hormone secretion and insulin release (7,8). Brain development and vaso-motor regulation have been reported for the TRPC subfamily channels (7-9), while the defining characteristic of the TRPP subfamily is their association with renal development (7-10). Evidence suggests that the TRPML subfamily is associated with endocytosis and the regulation of autophagy (7-9). The TRPA subfamily has been indicated to function as a thermo-sensor, chemo-sensor and olfactory sensor (6,7). The major physiological function of TRP family members in mammals are listed in Table I.

Mutations related to human diseases have been detected in nearly 30 members of the TRP channel family, which highlights their importance in human physiology, and they are likely to continue receiving attention in the future.

3. Structure, distribution and physiological function of TRPA1

Ankyrins are a group of linker proteins located on the membrane cytoskeleton that mediate the attachment of intact membrane proteins to spectrin and actin. TRPA1 was first isolated from human fetal lung fibroblasts in 1999 (11) and was originally called ankyrin-like with transmembrane domains protein 1 (12). It is the only known member of the TRPA subfamily and consists of 119 amino acid residues with a molecular weight of 127.4 kDa.

TRPA1 structure. As all TRP channels, TRPA1 is a tetrameric protein composed of four subunits (119 amino acids) and six transmembrane α -helices (S1-S6), with the pore loop structure located in the hydrophilic region between S5 and 6 (13,14). TRPA1 derives its name from 14-18 ankyrin repeats at the N-terminus (depending on species) in addition to a large number of active cysteine residues (15), which is an unusual structural feature and may be related to its interaction with intracellular components (16).

TRPA1 may be activated by a series of harmful external stimuli and endogenous signals related to cell damage. The latter includes cinnamaldehyde, allicin, allyl isothiocyanate and reactive oxygen species (17,18). The major mechanism of activation is the covalent modification of cysteine and lysine residues at the N-terminus of TRPA1 by highly electrophilic compounds (19). This mechanism promotes local

conformational changes, leading to the expansion of the pore loop structure, which increases the permeability to Ca^{2+} . In addition to being activated by reactive electrophiles and oxidants, TRPA1 may also be indirectly activated by the pro-inflammatory factor-mediated phospholipase C signal, in which cytoplasmic Ca^{2+} are an important regulator of channel gating (20). In addition, as TRPA1 is permeable to both univalent and bivalent cations (including Ca^{2+} , sodium and potassium), it is able to depolarise the membrane and activate Ca^{2+} signals (21). The structure of TRPA1 is presented in Fig. 1.

TRPA1 distribution. TRPA1 is a non-selective cation channel present in various tissues and organs, but it is mainly expressed in sensory neurons, such as primary sensory neurons in the lung, skin and brain, and peptidergic neurons (22), particularly those in the mammalian dorsal root ganglion, trigeminal ganglion, nodular ganglion and jugular ganglion (23).

In addition, TRPA1 is also present in several non-nerve cells and tissues, including vascular endothelial cells and chondrocytes (24,25), but the function of this expression has remained largely elusive. The major distribution of TRPA1 in the human body is presented in Fig. 2.

Physiological functions of TRPA1. TRPA1 is a cold-sensitive ion channel that may be activated to generate a stress response to endogenous and exogenous chemical stimulation, cold stimulation, mechanical stimulation and various inflammatory mediators. The activation of TRPA1 is closely related to the conduction and generation of cold sensation, the mediation of pain and analgesia, and the regulation of inflammatory substances.

TRPA1 is not mechanically sensitive under physiological conditions, but it may be activated at temperatures $< 17^\circ\text{C}$ (26); hence, it serves as a cold-sensitive receptor that detects changes in temperature in the internal and external environment. In addition to mediating temperature sensation and pain (27), TRPA1 functions in mechanical perception (28) and has a role in certain inflammatory states (29). Furthermore, TRPA1 is also associated with hypersensitivity and overexcitation in certain non-neuronal regions and has an important role in the pathophysiology of asthma, neuropathic pain, chronic itching, migraine, gastrointestinal motility disorders, anxiety and cognitive dysfunction (30-34).

Due to its individual characteristics in different organs, TRPA1 has been actively studied as a potential target for treating various diseases.

4. Ca^{2+} ions

Second messenger is one of the initiating components of intracellular signal transduction. Ca^{2+} , as an ubiquitous second messenger in the cytoplasm, is involved in the regulation of a variety of important physiological processes in cells, such as the synthesis and release of neurotransmitters, regulation of germ cell maturation and fertilization, and regulation of the activities of various enzymes in the body (35). Ca^{2+} is also closely related to hypertension, coronary heart disease, Alzheimer's disease (AD) and numerous other diseases (36-38). The intracellular second messenger Ca^{2+} has been a hot research topic in recent years.

Table I. TRP family members in mammals.

Subfamily	Main physiological function	(Refs.)
TRPV	Thermo-sensation; nociception; mechano-sensation; osmo-sensation	(6,7)
TRPM	Taste; gastric hormone secretion; insulin release	(7,8)
TRPC	Brain development; vaso-motor regulation	(7,9)
TRPP	Renal development	(7,10)
TRPML	Endocytosis and endosomal/lysosomal function; regulation of autophagy	(7,9)
TRPA	Thermo-sensation; chemo-sensing; nociception; olfactory responses	(6,7)

TRP, transient receptor potential channel; V, vanilloid; M, melastatin; C, canonical; P, polycystic; ML, mucolipin; A, ankyrin.




Figure 1. Structure of TRPA1 channel. The schematic diagram displays the six membrane-spanning helices (1-6) of the TRPA1 protein. The intracellular N and C termini are also displayed, along with the pore loop located between helices S5 and 6. TRPA1, transient receptor potential ankyrin 1; P, pore loop.

as well as between cytoplasm and organelles, is maintained and dynamically regulated according to cell needs through the cooperative work of a variety of ion channels, ion pumps and transporters (40). The major channels and transporters for intracellular Ca^{2+} cycling are presented in Fig. 3.

Abnormality of any link may cause instability of Ca^{2+} homeostasis. Ca^{2+} homeostasis is essential for cell maintenance; under pathological conditions, Ca^{2+} homeostasis is altered, with increased cytoplasmic Ca^{2+} concentrations. Ca^{2+} channels are a basis for revealing the regulatory laws of Ca^{2+} homeostasis and vital processes. Certain cation channels, including TRP family members, promote the influx of Ca^{2+} . For instance, although TRPA1 has high permeability to Ca^{2+} , Na^{+} and K^{+} , it has high Ca^{2+} selectivity. The PCa/PNa is 6 when the channel opens spontaneously and increases to 9 when the channel is activated by an electrophilic reagent (41).

5. Coupling TRPA1 with Ca^{2+} ions

TRPA1 mediates Ca^{2+} internal flow. Compared with most other TRP channels, TRPA1 has higher Ca^{2+} permeability. The N-terminus of TRPA1 contains two helical Ca^{2+} -binding motifs and the permeation pathway involves two major contraction sites (15), with an aspartate (D918 in mouse, D915 in human) within the pore loop that is critical for Ca^{2+} permeability (13). Total internal reflection fluorescence and confocal microscopy revealed that the signal generated by Ca^{2+} influx from a single TRPA1 channel in endothelial cells is at least 200 times that of L-type Ca^{2+} channels (42). This is because TRPA1 channels exist in the plasma membrane of endothelial cells with a tight binary structure. When one of a pair of channels is opened, afferent Ca^{2+} is able to bind to the Ca^{2+} -sensitive EF-Hand protein domain at the N-terminus, thereby triggering the adjacent channel (43).

There is a highly conserved structural motif in the TRPA1 channel that is the key site of intracellular Ca^{2+} elevation caused by Ca^{2+} storage (44), which explains various Ca^{2+} -dependent processes, including sensitisation, desensitisation and coupling with metabolic receptors. TRPA1-mediated Ca^{2+} influx is involved in various biological processes such as factor secretion (45) and gene transcription (46). TRPA1 is able to induce apoptosis in cardiomyocytes (47), oligodendrocytes (48) and hippocampal neurons (49) by regulating the Ca^{2+} concentration. Increasing evidence indicates that TRPA1-mediated Ca^{2+} influx has a role in determining the pathophysiological state.




Figure 2. Distribution of the TRPA1 channel in the body. TRPA1 is found in a subset of somatic (dorsal root, trigeminal) and visceral (nodose) primary sensory neurons and it is widely expressed in both neuronal and non-neuronal cells. TRPA1, transient receptor potential ankyrin 1.

The cytosolic free Ca^{2+} concentration in mammalian cells is generally controlled in the range of 100-200 nmol/l, while the Ca^{2+} concentration in extracellular organelles is kept in the order of mmol/l (39). The steep but tightly controlled concentration gradient of Ca^{2+} within and outside the cell membrane,

TRPA1 serves as a physiological medium for inflammatory signals and appears to perform a functional role in promoting myoblast migration, fusion and potential activation of human satellite cells. Thus, it may provide a novel target for treating muscle injury or muscle-related diseases via the formation of Ca²⁺/calmodulin complexes (61).

The inflammatory factor interleukin (IL)-1 β increases the functional expression of TRPA1, which leads to Ca²⁺ overload and a significant decrease in mitochondrial membrane potential. Inhibition of TRPA1 has a protective effect on mitochondrial dysfunction and even apoptosis of rat chondrocytes induced by IL-1 β (62). Furthermore, the TRPA1 channel may protect against intestinal fibrosis by mediating Ca²⁺ mobilisation, in addition to its anti-inflammatory actions (63).

A considerable amount of research has focused on the role of TRPA1 in nervous system regions and suggests that TRPA1 has a promising prospect in both peripheral and central nervous system regions (64-66).

Current therapies of multiple sclerosis mainly focus on pathological immune responses, but they cannot prevent the progression of clinical symptoms (67). TRPA1 regulates the functions of astrocytes by increasing the intracellular Ca²⁺ concentration (24).

Organophosphate-induced delayed neurotoxicity refers to a series of neurological symptoms that occur within 1-3 weeks after the ingestion of organophosphorus compounds (68). A study from the Shanghai Institute of Pharmacy, Chinese Academy of Sciences, discovered that TRPA1 is the major mediator of delayed neuropathy (69). In the same study, verapamil (an L-type Ca²⁺ channel blocker that effectively relieves the symptoms of the disease) was indicated to have a neuroprotective role by inhibiting TRPA1-mediated Ca²⁺ influx.

There is evidence to suggest that excessive Ca²⁺ in astrocytes may influence synaptic function, and regulating TRPA1 channel activity in astrocytes may provide a novel target for blocking early dysfunction in AD (70).

7. Conclusions and perspectives

After years of in-depth research, TRPA1 has attracted extensive clinical attention due to its function as a chemical sensor for irritation and cell damage, and its relationship with various diseases. For instance, hydrogen sulphide-mediated vasodilation is due to an increase in Ca²⁺ concentration in trigeminal ganglion neurons activated by TRPA1 (71). In addition, TRPA1 is an important subject of toxicology research and is actively studied by pharmaceutical companies (72). However, the functional regulatory mechanisms of TRPA1 remain poorly understood and further investigations may lead to novel protective strategies. In our opinion, areas worthy of further research include the following: i) Unveiling the specific mechanism of the interaction between TRPA1 and Ca²⁺; ii) exploring the therapeutic potential of TRPA1 in the treatment of pain and airway respiratory diseases through clinical studies; iii) assessing the potential of TRPA1 antagonist as a therapeutic target; and iv) investigating the mechanisms by which TRPA1 regulates Ca²⁺ in different diseases.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant nos. 81673227 and 81172712), the Natural Science Foundation of Hunan Province (grant no. 2020JJ4080) and the Key Projects of the Hunan Provincial Department of Education (grant no. 18A254).

Availability of data and materials

Not applicable.

Authors' contributions

FH: Writing-original draft preparation, review and editing. XS: Conceptualization. DL: Supervision, funding acquisition and manuscript revision. Data authentication is not applicable. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Sakaguchi R and Mori Y: Transient receptor potential (TRP) channels: Biosensors for redox environmental stimuli and cellular status. *Free Radic Biol Med* 146: 36-44, 2020.
2. Alavi MS, Shamsizadeh A, Karimi G and Roohbakhsh A: Transient receptor potential ankyrin 1 (TRPA1)-mediated toxicity: Friend or foe? *Toxicol Mech Methods* 30: 1-18, 2020.
3. Saotome K, Singh AK, Yelshanskaya MV and Sobolevsky AI: Crystal structure of the epithelial calcium channel TRPV6. *Nature* 534: 506-511, 2016.
4. Skerratt S: Recent progress in the discovery and development of TRPA1 modulators. *Prog Med Chem* 56: 81-115, 2017.
5. Li X and Fine M: TRP channel: The structural era. *Cell Calcium* 87: 102191, 2020.
6. Venkatachalam K and Montell C: TRP channels. *Annu Rev Biochem* 76: 387-417, 2007.
7. Nilius B and Flockerzi V: Mammalian transient receptor potential (TRP) cation channels. Preface. *Handb Exp Pharmacol* 223: 5-6, 2014.
8. Dhakal S and Lee Y: Transient receptor potential channels and metabolism. *Mol Cells* 42: 569-578, 2019.
9. Nilius B and Owsianik G: The transient receptor potential family of ion channels. *Genome Biol* 12: 218, 2011.
10. Samanta A, Hughes TET and Moiseenkova-Bell VY: Transient receptor potential (TRP) channels. *Subcell Biochem* 87: 141-165, 2018.
11. Laursen WJ, Anderson EO, Hoffstaetter LJ, Bagriantsev SN and Gracheva EO: Species-specific temperature sensitivity of TRPA1. *Temperature (Austin)* 2: 214-226, 2015.
12. Andrade EL, Meotti FC and Calixto JB: TRPA1 antagonists as potential analgesic drugs. *Pharmacol Ther* 133: 189-204, 2012.

13. Viana F: TRPA1 channels: Molecular sentinels of cellular stress and tissue damage. *J Physiol* 594: 4151-4169, 2016.
14. Preti D, Saponaro G and Szallasi A: Transient receptor potential ankyrin 1 (TRPA1) antagonists. *Pharm Pat Anal* 4: 75-94, 2015.
15. Paulsen CE, Armache JP, Gao Y, Cheng Y and Julius D: Structure of the TRPA1 ion channel suggests regulatory mechanisms. *Nature* 520: 511-517, 2015.
16. Talavera K, Startek JB, Alvarez-Collazo J, Boonen B, Alpizar YA, Sanchez A, Naert R and Nilius B: Mammalian transient receptor potential TRPA1 channels: From structure to disease. *Physiol Rev* 100: 725-803, 2020.
17. Hansted AK, Bhatt DK, Olesen J, Jensen LJ and Jansen-Olesen I: Effect of TRPA1 activator allyl isothiocyanate (AITC) on rat dural and pial arteries. *Pharmacol Rep* 71: 565-572, 2019.
18. Tsuchiya Y and Kawamata K: Allicin induces electrogenic secretion of chloride and bicarbonate ions in rat colon via the TRPA1 receptor. *J Nutr Sci Vitaminol (Tokyo)* 65: 258-263, 2019.
19. Nilius B and Szallasi A: Transient receptor potential channels as drug targets: From the science of basic research to the art of medicine. *Pharmacol Rev* 66: 676-814, 2014.
20. Zygmunt PM and Högestätt ED: TRPA1. *Handb Exp Pharmacol* 222: 583-630, 2014.
21. Veldhuis NA, Poole DP, Grace M, McIntyre P and Bunnett NW: The G protein-coupled receptor-transient receptor potential channel axis: Molecular insights for targeting disorders of sensation and inflammation. *Pharmacol Rev* 67: 36-73, 2015.
22. Bártai IZ, Horváth A, Pintér E, Helyes Z and Pozsgai G: Role of transient receptor potential ankyrin 1 ion channel and somatostatin sst4 receptor in the antinociceptive and anti-inflammatory effects of sodium polysulfide and dimethyl trisulfide. *Front Endocrinol (Lausanne)* 9: 55, 2018.
23. Kurganov E, Saito S, Tanaka Saito C and Tominaga M: Requirement of extracellular Ca²⁺ binding to specific amino acids for heat-evoked activation of TRPA1. *J Physiol* 595: 2451-2463, 2017.
24. Sághy É, Sipos É, Ács P, Bölskei K, Pohóczky K, Kemény Á, Sándor Z, Szóke É, Sétáló G Jr, Komoly S and Pintér E: TRPA1 deficiency is protective in cuprizone-induced demyelination—a new target against oligodendrocyte apoptosis. *Glia* 64: 2166-2180, 2016.
25. Nummenmaa E, Hämäläinen M, Moilanen LJ, Paukkeri EL, Nieminen RM, Moilanen T, Vuolteenaho K and Moilanen E: Transient receptor potential ankyrin 1 (TRPA1) is functionally expressed in primary human osteoarthritic chondrocytes. *Arthritis Res Ther* 18: 185, 2016.
26. Miyake T, Nakamura S, Zhao M, So K, Inoue K, Numata T, Takahashi N, Shirakawa H, Mori Y, Nakagawa T and Kaneko S: Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROS. *Nat Commun* 7: 12840, 2016.
27. Clapham DE: Structural biology: Pain-sensing TRPA1 channel resolved. *Nature* 520: 439-441, 2015.
28. Moparthi L and Zygmunt PM: Human TRPA1 is an inherently mechanosensitive bilayer-gated ion channel. *Cell Calcium* 91: 102255, 2020.
29. Moilanen LJ, Hämäläinen M, Lehtimäki L, Nieminen RM and Moilanen E: Urate crystal induced inflammation and joint pain are reduced in transient receptor potential ankyrin 1 deficient mice—potential role for transient receptor potential ankyrin 1 in gout. *PLoS One* 10: e0117770, 2015.
30. Yang Y, Wang S, Kobayashi K, Hao Y, Kanda H, Kondo T, Kogure Y, Yamanaka H, Yamamoto S, Li J, *et al*: TRPA1-expressing lamina propria mesenchymal cells regulate colonic motility. *JCI Insight* 4: e122402, 2019.
31. Gallo V, Dijk FN, Holloway JW, Ring SM, Koppelman GH, Postma DS, Strachan DP, Granell R, de Jongste JC, Jaddoe VW, *et al*: TRPA1 gene polymorphisms and childhood asthma. *Pediatr Allergy Immunol* 28: 191-198, 2017.
32. Logashina YA, Korolkova YV, Kozlov SA and Andreev YA: TRPA1 channel as a regulator of neurogenic inflammation and pain: Structure, function, role in pathophysiology, and therapeutic potential of ligands. *Biochemistry (Mosc)* 84: 101-118, 2019.
33. Benemei S and Dussor G: TRP channels and migraine: Recent developments and new therapeutic opportunities. *Pharmaceuticals (Basel)* 12: 54, 2019.
34. Lee KI, Lin HC, Lee HT, Tsai FC and Lee TS: Loss of transient receptor potential ankyrin 1 channel deregulates emotion, learning and memory, cognition, and social behavior in mice. *Mol Neurobiol* 54: 3606-3617, 2017.
35. Pan S, Ryu SY and Sheu SS: Distinctive characteristics and functions of multiple mitochondrial Ca²⁺ influx mechanisms. *Sci China Life Sci* 54: 763-769, 2011.
36. Chen Q, Zhang Y, Ding D, Li D, Yang Y, Li Q, Chen X, Hu G and Ling W: Associations between serum calcium, phosphorus and mortality among patients with coronary heart disease. *Eur J Nutr* 57: 2457-2467, 2018.
37. Popugaeva E, Pchitskaya E and Bezprozvanny I: Dysregulation of intracellular calcium signaling in Alzheimer's disease. *Antioxid Redox Signal* 29: 1176-1188, 2018.
38. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A and Montezano AC: Vascular smooth muscle contraction in hypertension. *Cardiovasc Res* 114: 529-539, 2018.
39. van der Kant R and Neefjes J: Small regulators, major consequences—Ca²⁺ and cholesterol at the endosome-ER interface. *J Cell Sci* 127: 929-938, 2014.
40. Moccia F, Berra-Romani R and Tanzi F: Update on vascular endothelial Ca(2+) signalling: A tale of ion channels, pumps and transporters. *World J Biol Chem* 3: 127-158, 2012.
41. Karashima Y, Prenen J, Talavera K, Janssens A, Voets T and Nilius B: Agonist-induced changes in Ca(2+) permeation through the nociceptor cation channel TRPA1. *Biophys J* 98: 773-783, 2010.
42. Sullivan MN, Gonzales AL, Pires PW, Bruhl A, Leo MD, Li W, Oulidi A, Boop FA, Feng Y, Jaggard JH, *et al*: Localized TRPA1 channel Ca²⁺ signals stimulated by reactive oxygen species promote cerebral artery dilation. *Sci Signal* 8: ra2, 2015.
43. Lin King JV, Emrick JJ, Kelly MJS, Herzig V, King GF, Medzihradsky KF and Julius D: A cell-penetrating scorpion toxin enables mode-specific modulation of TRPA1 and pain. *Cell* 178: 1362-1374.e16, 2019.
44. Zhao J, Lin King JV, Paulsen CE, Cheng Y and Julius D: Irritant-evoked activation and calcium modulation of the TRPA1 receptor. *Nature* 585: 141-145, 2020.
45. Andrei SR, Ghosh M, Sinharoy P, Dey S, Bratz IN and Damron DS: TRPA1 ion channel stimulation enhances cardiomyocyte contractile function via a CaMKII-dependent pathway. *Channels (Austin)* 11: 587-603, 2017.
46. Yin S, Wang P, Xing R, Zhao L, Li X, Zhang L and Xiao Y: Transient receptor potential ankyrin 1 (TRPA1) mediates lipopolysaccharide (LPS)-induced inflammatory responses in primary human osteoarthritic fibroblast-like synoviocytes. *Inflammation* 41: 700-709, 2018.
47. Wang Z, Wang M, Liu J, Ye J, Jiang H, Xu Y, Ye D and Wan J: Inhibition of TRPA1 attenuates doxorubicin-induced acute cardiotoxicity by suppressing oxidative stress, the inflammatory response, and endoplasmic reticulum stress. *Oxid Med Cell Longev* 2018: 5179468, 2018.
48. Liu M, Zhong S, Kong R, Shao H, Wang C, Piao H, Lv W, Chu X and Zhao Y: Paeonol alleviates interleukin-1 β -induced inflammatory responses in chondrocytes during osteoarthritis. *Biomed Pharmacother* 95: 914-921, 2017.
49. Yazğan Y and Nazıroğlu M: Ovariectomy-induced mitochondrial oxidative stress, apoptosis, and calcium ion influx through TRPA1, TRPM2, and TRPV1 are prevented by 17 β -estradiol, tamoxifen, and raloxifene in the hippocampus and dorsal root ganglion of rats. *Mol Neurobiol* 54: 7620-7638, 2017.
50. Hamilton NB, Kolodziejczyk K, Kougioumtzidou E and Attwell D: Proton-gated Ca(2+)-permeable TRP channels damage myelin in conditions mimicking ischaemia. *Nature* 529: 523-527, 2016.
51. Kádková A, Synytsya V, Krusek J, Zimová L and Vlachová V: Molecular basis of TRPA1 regulation in nociceptive neurons. A review. *Physiol Res* 66: 425-439, 2017.
52. Stueber T, Eberhardt MJ, Caspi Y, Lev S, Binshok A and Leffler A: Differential cytotoxicity and intracellular calcium-signalling following activation of the calcium-permeable ion channels TRPV1 and TRPA1. *Cell Calcium* 68: 34-44, 2017.
53. Hasan R and Zhang X: Ca²⁺ regulation of TRP ion channels. *Int J Mol Sci* 19: 1256, 2018.
54. Hasan R, Leeson-Payne AT, Jaggard JH and Zhang X: Calmodulin is responsible for Ca²⁺-dependent regulation of TRPA1 channels. *Sci Rep* 7: 45098, 2017.
55. Cordero-Morales JF, Gracheva EO and Julius D: Cytoplasmic ankyrin repeats of transient receptor potential A1 (TRPA1) dictate sensitivity to thermal and chemical stimuli. *Proc Natl Acad Sci USA* 108: E1184-E1191, 2011.

56. Moparthy L, Moparthy SB, Wenger J and Zygmunt PM: Calcium activates purified human TRPA1 with and without its N-terminal ankyrin repeat domain in the absence of calmodulin. *Cell Calcium* 90: 102228, 2020.
57. Kurganov E and Tominaga M: Dependence of heat-evoked TRPA1 activation on extracellular Ca²⁺. *Channels (Austin)* 11: 271-272, 2017.
58. Zurborg S, Yurgionas B, Jira JA, Caspani O and Heppenstall PA: Direct activation of the ion channel TRPA1 by Ca²⁺. *Nat Neurosci* 10: 277-279, 2007.
59. Takahashi N, Chen HY, Harris IS, Stover DG, Selfors LM, Bronson RT, Deraedt T, Cichowski K, Welm AL, Mori Y, *et al*: Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance. *Cancer Cell* 33: 985-1003.e7, 2018.
60. Derouiche S, Mariot P, Warnier M, Vancauwenberghe E, Bidaux G, Gosset P, Mauroy B, Bonnal JL, Slomianny C, Delcourt P, *et al*: Activation of TRPA1 channel by antibacterial agent triclosan induces VEGF secretion in human prostate cancer stromal cells. *Cancer Prev Res (Phila)* 10: 177-187, 2017.
61. Osterloh M, Böhm M, Kalbe B, Osterloh S and Hatt H: Identification and functional characterization of TRPA1 in human myoblasts. *Pflugers Arch* 468: 321-333, 2016.
62. Yin S, Zhang L, Ding L, Huang Z, Xu B, Li X, Wang P and Mao J: Transient receptor potential ankyrin 1 (trpa1) mediates il-1 β -induced apoptosis in rat chondrocytes via calcium overload and mitochondrial dysfunction. *J Inflamm (Lond)* 15: 27, 2018.
63. Kurahara LH, Hiraishi K, Hu Y, Koga K, Onitsuka M, Doi M, Aoyagi K, Takedatsu H, Kojima D, Fujihara Y, *et al*: Activation of myofibroblast TRPA1 by steroids and pirlfenidone ameliorates fibrosis in experimental crohn's disease. *Cell Mol Gastroenterol Hepatol* 5: 299-318, 2017.
64. Kheradpezhoh E, Choy JMC, Daria VR and Arabzadeh E: TRPA1 expression and its functional activation in rodent cortex. *Open Biol* 7: 160314, 2017.
65. Kittaka H and Tominaga M: The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin. *Allergol Int* 66: 22-30, 2017.
66. Bölcskei K, Kriszta G, SÁghy É, Payrits M, Sipos É, Vranesics A, Berente Z, Ábrahám H, Ács P, Komoly S and Pintér E: Behavioural alterations and morphological changes are attenuated by the lack of TRPA1 receptors in the cuprizone-induced demyelination model in mice. *J Neuroimmunol* 320: 1-10, 2018.
67. Habek M: Immune and autonomic nervous system interactions in multiple sclerosis: Clinical implications. *Clin Auton Res* 29: 267-275, 2019.
68. Richardson RJ, Fink JK, Glynn P, Hufnagel RB, Makhaeva GF and Wijeyesakere SJ: Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN). *Adv Neurotoxicol* 4: 1-78, 2020.
69. Ding Q, Fang S, Chen X, Wang Y, Li J, Tian F, Xu X, Attali B, Xie X and Gao Z: TRPA1 channel mediates organophosphate-induced delayed neuropathy. *Cell Discov* 3: 17024, 2017.
70. Bosson A, Paumier A, Boisseau S, Jacquier-Sarlin M, Buisson A and Albrieux M: TRPA1 channels promote astrocytic Ca²⁺ hyperactivity and synaptic dysfunction mediated by oligomeric forms of amyloid- β peptide. *Mol Neurodegener* 12: 53, 2017.
71. Hajna Z, SÁghy É, Payrits M, Aubdool AA, Szőke É, Pozsgai G, Bártai IZ, Nagy L, Filotás D, Helyes Z, *et al*: Capsaicin-sensitive sensory nerves mediate the cellular and microvascular effects of H₂S via TRPA1 receptor activation and neuropeptide release. *J Mol Neurosci* 60: 157-170, 2016.
72. Kaneko Y and Szallasi A: Transient receptor potential (TRP) channels: A clinical perspective. *Br J Pharmacol* 171: 2474-2507, 2014.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.